Results 11 to 20 of about 83,985 (257)
Frontiers in Immunology, 2022 The outcomes of 80 patients with hematologic malignancies who received haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) combined with unrelated cord blood (UCB) from March 2017 to June 2020 were analyzed in this retrospective study.
Cong Zeng +35 more
doaj +1 more source
Hematological Neoplasms with Eosinophilia
Cancers, 2023 Eosinophils in peripheral blood account for 0.3–5% of leukocytes, which is equivalent to 0.05–0.5 × 109/L. A count above 0.5 × 109/L is considered to indicate eosinophilia, while a count equal to or above 1.5 × 109/L is defined as hypereosinophilia. In bone marrow aspirate, eosinophilia is considered when eosinophils make up more than 6% of the total ...
Rosario M. Morales-Camacho +4 more
openaire +5 more sources
Frontiers in Oncology, 2022 Recent studies have shown that haploidentical hematopoietic stem cell transplantation supported by third-party cord blood (haplo-cord-HSCT) results in rapid hematopoietic recovery, low incidences of graft-versus-host disease (GVHD), and relapse of ...
Tingting Cheng +31 more
doaj +1 more source
Cells, 2021 Myeloproliferative neoplasms are hematologic malignancies typified by a substantial heritable component. Germline variants may affect the risk of developing a MPN, as documented by GWAS studies on large patient cohorts. In addition, once the MPN occurred,
Elena Masselli +3 more
doaj +1 more source
Screening for SARS-COV-2 Using RT-qPCR in Patients with Hematologic Neoplasms Receiving Chemotherapy
Prague Medical Report, 2023 It has been recommended that patients with leukaemias and lymphomas undergo universal screening for SARS-COV-2 using RT-qPCR before each treatment on the grounds of their high risk of experiencing severe forms of COVID-19.
Ignacio Martín Santarelli +2 more
doaj +1 more source
The Role of TET2 in Hematologic Neoplasms [PDF]
Cancer Cell, 2011 TET2 encodes an enzyme that hydroxylates methylcytosine and is frequently targeted by loss-of-function mutations in myelodysplasia, myeloproliferative disorders, and acute myeloid leukemia. In this issue of Cancer Cell, two studies show that inactivation of Tet2 enhances hematopoietic stem cell self renewal and promotes the development of ...
Holmfeldt, Linda, Mullighan, Charles G.
openaire +2 more sources
GENETIC PREDISPOSITION TO HEMATOLOGIC MALIGNANCIES IN CHILDHOOD AND ADOLESCENCE
Mediterranean Journal of Hematology and Infectious Diseases, 2023 Advances in molecular biology and genetic testing have greatly improved our understanding of the genetic basis of hematologic malignancies and have enabled the identification of new cancer predisposition syndromes. The recognition of a germline mutation
Francesco Fabozzi, Angela Mastronuzzi
doaj +1 more source
Immunotherapy in Pediatric Hematologic Malignant Neoplasms
Clinical Pediatric Hematology-Oncology, 2020 Childhood acute leukemia has achieved tremendous treatment outcome improvement over the past several decades. Given that pediatric leukemia remains the most common type of childhood malignant tumors, there are still unmet needs in relapsed/refractory ...
Kyung Taek Hong
doaj +1 more source
Nature Communications, 2023 Genomic profiling of hematologic malignancies has augmented our understanding of variants that contribute to disease pathogenesis and supported development of prognostic models that inform disease management in the clinic.
Ryan N. Ptashkin +54 more
doaj +1 more source
Journal of Applied Hematology, 2021 Systemic mastocytosis (SM) characterized by focal or diffuse infiltrates of neoplastic mast cells can range from indolent cutaneous disease to aggressive systemic disease.
B R Rajalakshmi, Vijaya Basavaraj
doaj +1 more source